Shares of Labcorp Holdings Inc. LH slid 2.16% to $277.74 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.28% to 7,482.71 ...

Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Patients who get blood work through Labcorp can now receive AI-generated plain-language explanations of their results inside ...

Labcorp Holdings will report its second-quarter results by the end of this month, and analysts are anticipating a ...

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered ...

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on ...

A healthcare company is preparing to pay $35,000,000 to settle a class action lawsuit over a cybersecurity incident that ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

Shares of Labcorp Holdings Inc. LH rallied 1.39% to $283.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 7,483 ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Physician-founded telehealth service provides on-demand lab orders through LabCorp & Quest, helping patients maintain ...